An observational study in Leukemia, Leukemia, Myeloid and Leukemia, Lymphoblastic, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by University of Zurich · Observational
Among 67 studies in Leukemia with a site in Switzerland — 9 open to participants now, 12 under way, 2 of them phase 3. Leukemia · Switzerland.
Among the 67 studies in Leukemia with a site in Switzerland, this one is one of 4 that started in 2024, is one of 7 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 65th registered.
2,381 studies on the registry are indexed under Leukemia; 253 are open to participants now.
This study's planned enrollment of 130 is close to the median of 142 across 332 observational studies indexed under Leukemia.
Browse Leukemia studies →9 of the 67 studies in Leukemia with a site in Switzerland are open now, in 12 countries. Each count lists the studies.
Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →67 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 4 started in 2024.
Median enrollment 110 across the 60 interventional studies, 130 across the 7 observational. Of the 48 that completed or were terminated, 10 (21%) have results posted.
18 of 67 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,049 studies on the registry; 133 are open to participants now.
University of Zurich has 2 studies filed under Leukemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Leukemia with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06430736Insel Gruppe AG, University Hospital BernPRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) | 2026-12 |
| NCT06861530University Children's Hospital BaselA Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children | 2026-12-31 |
| NCT06537726University of ZurichBreath Analysis for the Detection of Invasive Fungal Infections | 2027-10-31 |
Among the 67 studies in Leukemia with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity.
With the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).
Patients with acute leukemia that are undergoing chemotherapy at the Department of Medical Oncology and Haematology at the University Hospital Zurich
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients, that retrospectively do not have evidence of IFI
Diagnostic Test: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Patients, that retrospectively have a possible IFI (according to EORTC guidelines). There is suspicion of IFI by clinical or radiological features, but no microbiological evidence of IFI.
Diagnostic Test: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Patients, that retrospectively have a probable IFI (according to EORTC guidelines). There is suspicion of IFI by clinical or radiological features, and indirect microbiological evidence of IFI.
Diagnostic Test: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Patients, that retrospectively have a proven IFI (according to EORTC guidelines). There is histological (angioinvasive growth of a fungus) or definitive microbiological evidence of IFI, e.g. evidence of a fungus from a sterile tissue.
Diagnostic Test: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
Also known as: Blood sampling (serologic biomarkers, PCR), Sputum analysis, Low-dose CT
Novel biomarker (m/z value) for IFI by SESI-HRMS
Feature in Mass Spectrometry
Time frame: through study completion, on average after 3 weeks
Specificity and sensitivity of this novel biomarker
Description of Accuracy and Precision of this novel biomarker
Time frame: through study completion, on average after 3 weeks
Anticipation of IFI
Timepoint of first detection in relation to first clinical symptoms of IFI
Time frame: through study completion, on average after 3 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Oct 2027, 38 months after the start.
Of 96 non-industry observational studies under Leukemia, half reached primary completion within 119 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 269. This study's planned 38 months is below that.
Counting every sponsor, half of 110 studies reached it within 119 months; a quarter within 40 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.